Master Rollover Protocol for Continued Safety Assessment of Study Drug

Available (expanded access)

Conditions studied: Cancer

In brief

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Key facts

Study ID

NCT02632994

Run by

Eli Lilly and Company

Last updated by the study team

2026-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

You may not qualify if…

• Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Where it is running

• UCLA Medical Center — Torrance, California, United States
• Fort Wayne Oncology & Hematology — Fort Wayne, Indiana, United States
• Sarah Cannon Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.